#ESC22: Bay­er's fac­tor XIa in­hibitor miss­es ef­fi­ca­cy marks in 2 PhII stud­ies but com­pa­ny dives straight in­to PhI­II

BARCELONA — Bay­er’s fac­tor XIa in­hibitor didn’t clear the hur­dle in cer­tain pri­ma­ry ef­fi­ca­cy marks in two Phase II clin­i­cal stud­ies, tri­al in­ves­ti­ga­tors said Sun­day morn­ing at the Eu­ro­pean So­ci­ety of Car­di­ol­o­gy Con­gress.

Bris­tol My­ers Squibb and John­son & John­son’s fac­tor XIa in­hibitor al­so flopped on a com­pos­ite pri­ma­ry end­point in their own Phase II study, pre­sent­ed short­ly af­ter Bay­er on Sun­day morn­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER